140 related articles for article (PubMed ID: 38281385)
1. Point-of-care HCV RNA testing improves hepatitis C testing rates and allows rapid treatment initiation among people who inject drugs attending a medically supervised injecting facility.
MacIsaac MB; Whitton B; Anderson J; Cogger S; Vella-Horne D; Penn M; Weeks A; Elmore K; Pemberton D; Winter RJ; Papaluca T; Howell J; Hellard M; Stoové M; Wilson D; Pedrana A; Doyle JS; Clark N; Holmes JA; Thompson AJ
Int J Drug Policy; 2024 Mar; 125():104317. PubMed ID: 38281385
[TBL] [Abstract][Full Text] [Related]
2. Eliminating hepatitis C in Australia: a novel model of hepatitis C testing and treatment for people who inject drugs at a medically supervised injecting facility.
MacIsaac MB; Whitton B; Hubble A; Cogger S; Penn M; Weeks A; Elmore K; Pemberton D; Anderson J; Howard R; McKeever U; Papaluca T; Hellard ME; Stoove M; Wilson D; Pedrana A; Doyle J; Clark N; Holmes J; Thompson AJ
Med J Aust; 2023 Apr; 218(6):256-261. PubMed ID: 36919230
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with hepatitis C testing, treatment, and current hepatitis C infection among men and women who inject drugs: The ETHOS engage study.
Valerio H; Marshall AD; Conway A; Treloar C; Carter L; Martinello M; Henderson C; Amin J; Read P; Silk D; Degenhardt L; Prain B; Alavi M; Dore GJ; Grebely J;
Int J Drug Policy; 2024 May; 127():104394. PubMed ID: 38608357
[TBL] [Abstract][Full Text] [Related]
4. Integration of Hepatitis C and Addiction Treatment in People Who Inject Drugs: The San Patrignano HCV-Free and Drug-Free Experience.
Piselli P; Boschini A; Gianfreda R; Nappo A; Cimaglia C; Scarfò G; Smacchia C; Paoletti R; Duehren S; Girardi E
Viruses; 2024 Feb; 16(3):. PubMed ID: 38543741
[TBL] [Abstract][Full Text] [Related]
5. Does a simplified algorithm and integrated HCV care model improve linkage to care, retention, and cure among people who inject drugs? A pragmatic quality improvement randomized controlled trial protocol.
Klaman SL; Godino JG; Northrup A; Lewis SV; Tam A; Carrillo C; Lewis R; Matthews E; Mendez B; Reyes L; Rojas S; Ramers C
BMC Infect Dis; 2024 Jan; 24(1):105. PubMed ID: 38238686
[TBL] [Abstract][Full Text] [Related]
6. Towards elimination of hepatitis C in Oslo: Cross-sectional prevalence studies among people who inject drugs.
Opheim E; Dalgard O; Ulstein K; Sørli H; Backe Ø; Foshaug T; Couëssurel Wüsthoff LE; Midgard H
Int J Drug Policy; 2024 Jan; 123():104279. PubMed ID: 38061225
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Xpert HCV VL Fingerstick point-of-care assay and dried blood spot HCV-RNA testing as simplified diagnostic strategies among people who inject drugs in Catalonia, Spain.
Saludes V; Antuori A; Lazarus JV; Folch C; González-Gómez S; González N; Ibáñez N; Colom J; Matas L; Casabona J; Martró E
Int J Drug Policy; 2020 Jun; 80():102734. PubMed ID: 32470849
[TBL] [Abstract][Full Text] [Related]
8. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies.
Sacks-Davis R; van Santen DK; Boyd A; Young J; Stewart A; Doyle JS; Rauch A; Mugglin C; Klein M; van der Valk M; Smit C; Jarrin I; Berenguer J; Lacombe K; Requena MB; Wittkop L; Leleux O; Bonnet F; Salmon D; Matthews GV; Guy R; Martin NK; Spelman T; Prins M; Stoove M; Hellard M;
Lancet HIV; 2024 Feb; 11(2):e106-e116. PubMed ID: 38224708
[TBL] [Abstract][Full Text] [Related]
9. Decentralised same day test and treatment of hepatitis C levering existing peer support networks among men who inject drugs: feasibility and effectiveness.
Rajkumar N; Khumukcham LS; Thangjam D; Singh S; Khwairakpam G; Shilton S; Goel A
Harm Reduct J; 2024 May; 21(1):98. PubMed ID: 38769517
[TBL] [Abstract][Full Text] [Related]
10. Global, regional, and country-level coverage of testing and treatment for HIV and hepatitis C infection among people who inject drugs: a systematic review.
Hajarizadeh B; Kairouz A; Ottaviano S; Ireland J; Willing A; Cunningham E; Webb P; Colledge-Frisby S; Wheeler A; Leung J; Tran LT; Price O; Vickerman P; Farrell M; Hickman M; Dore GJ; Bergenström A; Degenhardt L; Grebely J
Lancet Glob Health; 2023 Dec; 11(12):e1885-e1898. PubMed ID: 37973339
[TBL] [Abstract][Full Text] [Related]
11. Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study.
Grebely J; Gilliver R; McNaughton T; Conway A; Cunningham E; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Read P
Int J Drug Policy; 2023 Apr; 114():103982. PubMed ID: 36863287
[TBL] [Abstract][Full Text] [Related]
12. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.
Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J;
Int J Drug Policy; 2022 Jul; 105():103706. PubMed ID: 35533635
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C screening in Lithuania: first-year results and scenarios for achieving WHO elimination targets.
Petkevičienė J; Voeller A; Čiupkevičienė E; Razavi-Shearer D; Liakina V; Jančorienė L; Kazėnaitė E; Zaksas V; Urbonas G; Kupčinskas L
BMC Public Health; 2024 Apr; 24(1):1055. PubMed ID: 38622549
[TBL] [Abstract][Full Text] [Related]
14. All-cause mortality before and after DAA availability among people living with HIV and HCV: An international comparison between 2010 and 2019.
Requena MB; Protopopescu C; Stewart AC; van Santen DK; Klein MB; Jarrin I; Berenguer J; Wittkop L; Salmon D; Rauch A; Prins M; van der Valk M; Sacks-Davis R; Hellard ME; Carrieri P; Lacombe K;
Int J Drug Policy; 2024 Feb; 124():104311. PubMed ID: 38184902
[TBL] [Abstract][Full Text] [Related]
15. Temporal trends in HCV treatment uptake and success among people who inject drugs in Baltimore, MD since the introduction of direct acting antivirals.
Coyle CR; Gicquelais RE; Genberg BL; Astemborski J; Falade-Nwulia O; Kirk GD; Thomas DL; Mehta SH
Drug Alcohol Depend; 2023 Dec; 253():. PubMed ID: 38456165
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of assisted partner services for people who inject drugs in Kenya to identify partners living with HIV and hepatitis C virus infection: a prospective cohort study.
Monroe-Wise A; Mbogo L; Sambai B; Ludwig-Barron N; Guthrie BL; Bukusi D; Chohan BH; Masyuko S; Scott J; Juma E; Macharia P; Kingston H; Sinkele W; Gitau E; Bosire R; Musyoki H; Herbeck J; Farquhar C
Lancet Glob Health; 2024 May; 12(5):e859-e867. PubMed ID: 38614633
[TBL] [Abstract][Full Text] [Related]
17. Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trial.
Grebely J; Read P; Cunningham EB; Weltman M; Matthews GV; Dunlop A; Montebello M; Martinello M; Gilliver R; Marks P; Applegate TL; Dore GJ;
Health Sci Rep; 2020 Jun; 3(2):e151. PubMed ID: 32270056
[TBL] [Abstract][Full Text] [Related]
18. Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia.
Bajis S; Maher L; Treloar C; Hajarizadeh B; Lamoury FMJ; Mowat Y; Schulz M; Marshall AD; Cunningham EB; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Whelan M; Martinello M; Applegate TL; Dore GJ; Grebely J;
Int J Drug Policy; 2018 Nov; 61():23-30. PubMed ID: 30388566
[TBL] [Abstract][Full Text] [Related]
19. Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study.
Valerio H; Alavi M; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Dore GJ; Grebely J
Clin Infect Dis; 2021 Jul; 73(1):e69-e78. PubMed ID: 32421194
[TBL] [Abstract][Full Text] [Related]
20. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
